Condition

Stage IIIC Prostate Cancer AJCC v8

ClinicalTrials.gov condition label

How to interpret these research links

Connected source records

This is the original ClinicalTrials.gov condition label, found in 30 distinct published trials. It is kept separate from a MONDO disease identifier until a specific normalization is supported. Related interventions are co-recorded in studies; they are not medical recommendations.

Data basis: current published ClinicalTrials.gov records and, where present, RxNorm, MONDO and FDA-label identifiers. See the evidence interpretation and counting methodology.

Clinical trials30

Recruiting5

Common interventions25

Lead sponsors shown12

Clinical trials

30 shown

Extending Prostate Genetic Awareness, Navigation, and Delivery: The EXPAND NetworkNCT05627219 · 2024-06-03

Carboplatin Chemotherapy Before Surgery for People With High-Risk Prostate Cancer and an Inherited BRCA1 or BRCA2 Gene MutationNCT05806515 · 2024-03-01

High Dose-Rate Brachytherapy and Stereotactic Body Radiotherapy for the Treatment of Prostate AdenocarcinomaNCT04945642 · 2021-08-20

Androgen Ablation Therapy With or Without Niraparib After Radiation Therapy for the Treatment of High-Risk Localized or Locally Advanced Prostate CancerNCT04947254 · 2021-08-05

Proton Radiation Therapy for the Treatment of Patients With High Risk Prostate CancerNCT04725903 · 2021-02-01

MRI Guided Radiation Therapy for the Treatment of High Risk Prostate CancerNCT05676463 · 2022-11-16

RElugolix VErsus LeUprolide Cardiac TrialNCT05320406 · 2022-06-06

ACTIVE_NOT_RECRUITING

Robot-Assisted Radical Prostatectomy With or Without Vesicopexy in Patients With Prostate CancerNCT04981834 · 2021-10-27

Pharmacokinetics of IA and IV Ga68-PSMA-11 InfusionNCT04976257 · 2021-10-13

Extremely Hypofractionated Intensity Modulated Stereotactic Body Radiotherapy for the Treatment of Prostate Cancer With Rising PSA After Radical ProstatectomyNCT04915508 · 2021-06-23

ACTIVE_NOT_RECRUITING

White Button Mushroom Sup for the Reduction of PSA in Pts With Biochemically Rec or Therapy Naive Fav Risk Prostate CANCT04519879 · 2021-05-10

Health Literacy in Understanding Radiation Therapy Information in Patients Undergoing Definitive Radiation TherapyNCT04927559 · 2020-12-18

Technology-Enhanced Acceleration of Germline Evaluation for Therapy, TARGET StudyNCT04447703 · 2020-08-27

Randomized Trial of PSMA PET Scan Before Definitive Radiation Therapy for Prostate CancerNCT04457245 · 2020-08-14

An Investigational Scan (7 Tesla MRI) in Diagnosing Cognitive Impairment in Patients With Non-Metastatic Prostate CancerNCT04318028 · 2020-08-11

Lifestyle Behavior Influences Among African American Patients With Stage 0-III Prostate Cancer Survivors and Their PartnersNCT04189770 · 2020-02-26

ACTIVE_NOT_RECRUITING

Daily, Long-Term Intermittent Fasting for the Prevention of PSA-Recurrence in Patients With Localized Prostate Cancer After Radical ProstatectomyNCT04288336 · 2020-01-08

Remote Telemonitoring of Patient-Generated Physiologic Health Data and Patient-Reported OutcomesNCT04501913 · 2019-12-24

Aspirin and Rintatolimod With or Without Interferon-alpha 2b in Treating Patients With Prostate Cancer Before SurgeryNCT03899987 · 2019-11-29

ACTIVE_NOT_RECRUITING

Testing the Addition of a New Anti-Cancer Drug, Niraparib, to the Usual Treatment (Hormone and Radiation Therapy) for Prostate Cancer With a High Chance of RecurringNCT04037254 · 2019-10-08

Lifestyle Intervention for the Reduction of Prostate Cancer Disparities Among African AmericansNCT04215029 · 2019-08-27

ACTIVE_NOT_RECRUITING

A Phase I Study of SOR-C13 in Patients With Advanced Solid TumorsNCT03784677 · 2019-07-29

Genetic Analysis of Blood and Tissue Samples From Patients With Advanced Cancer, Moonshot StudyNCT03707574 · 2019-07-16

Pharmacogenomics Testing in the Optimal Use of Supportive Care Medications in Stage III-IV CancerNCT04067960 · 2019-06-06

Hyperpolarized Carbon C 13 Pyruvate Magnetic Resonance Spectroscopic Imaging in Predicting Treatment Response in Patients With Prostate CancerNCT03581500 · 2019-02-06

PI3Kbeta Inhibitor AZD8186 and Docetaxel in Treating Patients Advanced Solid Tumors With PTEN or PIK3CB Mutations That Are Metastatic or Cannot Be Removed by SurgeryNCT03218826 · 2018-09-24

Hypofractionated Radiation Therapy for Treating Prostate Cancer High-Risk Features Following Radical ProstatectomyNCT03570827 · 2018-05-14

Watchful Living in Improving Quality of Life in Participants With Localized Prostate Cancer on Active Surveillance and Their PartnersNCT03575832 · 2018-01-25

ACTIVE_NOT_RECRUITING

Apalutamide and Gonadotropin-Releasing Hormone Analog With or Without Abiraterone Acetate in Treating Participants With Prostate CancerNCT03279250 · 2017-10-13

Daratumumab or FMS Inhibitor JNJ-40346527 Before Surgery in Treating Patients With High-Risk, Resectable Localized or Locally Advanced Prostate CancerNCT03177460 · 2017-06-07

Common interventions

Leading sponsors

M.D. Anderson Cancer Center 8 Jonsson Comprehensive Cancer Center 3 Mayo Clinic 3 Thomas Jefferson University 3 University of Southern California 3 City of Hope Medical Center 2 Emory University 2 National Cancer Institute (NCI) 2 NRG Oncology 1 Roswell Park Cancer Institute 1 Ryan Kohlbrenner, MD 1 SWOG Cancer Research Network 1

Trial status mix

COMPLETED12

ACTIVE_NOT_RECRUITING6

RECRUITING5

TERMINATED3

SUSPENDED2

WITHDRAWN2

Phase mix

PHASE211

NA7

PHASE14

EARLY_PHASE13

PHASE31

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.